Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Twenty-eight-day mortality per pathogen minimum inhibitory concentration (MIC) in the 79 episodes of A. baumannii, P. aeruginosa, or K. pneumoniae isolated in respiratory samples obtained at baseline

From: Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial

 Colistin + levofloxacin group (n = 120), death/total number of cases (%)Meropenem + levofloxacin group (n = 112), death/total number of cases (%)p value
VAP caused by A. baumannii, P. aeruginosa, and K. pneumoniae (n = 79)40 (48.8)39 (52)0.811
MIC distribution
 Meropenem MIC
  ≤ 2 mg/l—susceptible4/16 (25)5/18 (27.8)0.885
  > 2–8 mg/l—intermediate0/4 (0)0/5 (0)
  > 8 mg/l—resistant5/20 (25)6/16 (37.5)0.419
 Colistin MIC
  ≤ 2 mg/l—susceptible9/35 (25.7)8/32 (25)0.947
  > 2 mg/l—resistant0/5 (0)3/7 (42.9)0.091
  1. MIC minimum inhibitory concentration, VAP ventilator-associated pneumonia